Global Statistics

All countries
180,370,780
Confirmed
Updated on June 24, 2021 5:27 am
All countries
163,374,630
Recovered
Updated on June 24, 2021 5:27 am
All countries
3,907,592
Deaths
Updated on June 24, 2021 5:27 am

Global Statistics

All countries
180,370,780
Confirmed
Updated on June 24, 2021 5:27 am
All countries
163,374,630
Recovered
Updated on June 24, 2021 5:27 am
All countries
3,907,592
Deaths
Updated on June 24, 2021 5:27 am

Could the antibody cocktail used in Trump’s treatment be a ‘game changer’ in India’s Kovid fight?

Digital Desk, New Delhi. 84-year-old Mohabbat Singh from Haryana was given an antibody cocktail which was also given to former US President Donald Trump. Mohabbat Singh is the first patient in the country who was given the antibody cocktail drug of Roche India and Cipla. After delivering the cocktail, Singh was kept under observation and then discharged from the hospital. The monoclonal antibody cocktail is being described as a game changer in the fight against Kovid. Studies have shown that 80% of patients taking this drug did not require hospitalization.

justify;">The most famous example is that of Donald Trump, who became infected with Corona last year. He returned to work within a week. However, this cocktail of monoclonal antibody drug is quite expensive. Cipla is marketing the drug in hospitals at an estimated price of Rs 59,000 per dose. The patient needs only one dose of this cocktail to recover. In an interview to ANI, Dr. Arvinder S. Soin of Medanta Hospital said that the production of monoclonal antibody drugs at a reasonable price in India can be a game changer for the country.

Dr. Arvinder S. Soin reports that the US Food and Drug Administration’s (FDA)-authorized three-specific drug (monoclonal antibody drug) and India’s Central Drug Standard Control Organization (CDSCO)-authorized drug can ‘root out kovid infection’ is. Dr. Soin stated that the drug should be given immediately after the patient’s positive test and certainly in the first week of infection. This can prevent serious illnesses and deaths.

Dr. Nirmal K Ganguly, former Director General of ICMR, said, ‘Since this (monoclonal antibody) is a highly expensive product, do not use it for all covid-infected individuals. Use it only for people with severe infections who are hospitalized. Dr. Raman R. Gangakhedkar, former chief scientist of ICMR, said, in the next few days, we will come to know how monoclonal antibodies are working against Kovid and its variants.

Dr. Ganguly told ANI that the cost of monoclonal antibody therapy can be reduced if a very efficient system is developed for its manufacture. The former DG of ICMR stated, nowadays monoclonal antibodies are produced through the mammalian cell culture system and can be produced in large quantities through fermentation technology.

Therapy is a cocktail of two monoclonal antibodies. Antibodies are proteins that the body produces to protect against any disease. Monoclonal antibodies are artificially made in a laboratory. It is prepared according to the fight against any disease. In any covid patient, normal antibodies develop only after 14 days of infection. But lab-produced antibodies work immediately in this drug.

Kasirivimab and imdevimab have been specifically formulated to act against the spike protein of the covid pandemic virus SARS-CoV-2. It blocks the attachment of the virus and then its entry into human cells. The dose of 600–600 mg of both antibodies is given in this cocktail. It can be stored at a temperature of 2–8 ° C.

.



Source link

Leave a Reply

Hot Topics

Related Articles

You cannot copy content of this page
%d bloggers like this: